pancreatic cancer
Conditions
Sponsors
Yamazaki Kana
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Healthy male subjects aged 20 or older and under 65 at the time of informed consent 2. Subjects who provide written informed consent 3. Subjects with BMI of less than 25
Exclusion criteria
Exclusion criteria: 1. Subjects who have severe or progressive complications 2. Subjects who have obvious abnormalities in physical and laboratory examinations after obtaining the informed consent 3. Subjects who have past history of severe drug hypersensitivity 4. Subjects with drug or alcohol addiction 5. Subjects who smoke 6. Subjects who have received medication or used vitamins, herbal medicines or supplements within14 days prior to their visit 7. Subjects who are claustrophobic 8. Subjects who have undergone an examination with radiation exposure for the purpose of medical treatment (X-ray, CT, PET, DEXA, etc.) within the past 12 months, or for the purpose of research within the past 6 months. Chest X-rays conducted as part of the annual medical check are excluded. 9. Subjects who are considered to be inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of [11C]MePro in human subjects Radiation dosimetry of [11C]MePro in human subjects | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of [11C]MePro | — |
Contacts
Public ContactKana Yamazaki
National Institute for Quantum Science and Technology
Outcome results
None listed